Patents by Inventor Edward Orton

Edward Orton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dihydrogen phosphate salt of a prostaglandin D2 receptor antagonist
    Patent number: 7642249
    Abstract: The present invention is directed to dihydrogen phosphate salt 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obs
    Type: Grant
    Filed: April 11, 2008
    Date of Patent: January 5, 2010
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Beverly Langevin, Edward Orton, Daniel Sherer
  • DIHYDROGEN PHOSPHATE SALT OF A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST
    Publication number: 20080194600
    Abstract: The present invention is directed to dihydrogen phosphate salt 2-(3-{6-[2-(2,4-dichloro-phenyl)-ethylamino]-2-methoxy-pyrimidin-4-yl}-phenyl)-2-methyl-propionic acid of Formula (III), a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of Formula (III), and a pharmaceutically acceptable carrier; and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obs
    Type: Application
    Filed: April 11, 2008
    Publication date: August 14, 2008
    Applicant: AVENTIS PHARMACEUTICALS INC
    Inventors: Beverly LANGEVIN, Edward ORTON, Daniel SHERER
  • Method and reagents for the quantification of solid-phase reactions using fluorine NMR
    Patent number: 6599753
    Abstract: This invention is directed to the use of 19F NMR spectroscopy to monitor and quantitate solid-phase reactions and fluorine-containing solid-phase reagents useful therefor.
    Type: Grant
    Filed: June 23, 1999
    Date of Patent: July 29, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Vasant K. Nagulapalli, Edward Orton, John E. Airey, Paul H. Krolikowski, Joseph M. Salvino
  • Cyclic ester dienes, polymeric and other derivatives thereof
    Patent number: 4525540
    Abstract: Novel dibasic organic acid diesters of the dienol form of biacetyl and methods for their preparation are provided. The compounds find use as monomers in homo- and copolymers, and the resulting polymers may be further modified to produce a variety of products.
    Type: Grant
    Filed: January 28, 1983
    Date of Patent: June 25, 1985
    Assignee: Washington Research Foundation
    Inventors: Boris Weinstein, Edward Orton